ABOUT US
Clinical Stage CAR-T for AL Amyloidosis and select immune-mediated diseases
Imagine a world where patients with AL amyloidosis and immune-mediated diseases can access a one-time, transformative treatment right at their doorstep. At ImmixBio, we see a horizon where this is possible.
Based on the groundbreaking cell therapy research in the early 2010s of Dr. Carl June at University of Pennsylvania, Dr. Renier Brentjens formerly of Memorial Sloan Kettering, and others, the first cell therapies were approved in the United States in August and October 2017, Kymriah® and Yescarta® for certain types of blood cancers.
Since then, the United States has seen a blossoming of experts in the field, manufacturing sites, as well as clinical and patient experience in the cell therapy space. Despite this progress, due to neurotoxicity and other side effects, 95% of U.S. medical centers are unable to dose these pioneering CAR-T cell therapies. Additionally, also due to neurotoxicity and other side effects, only a narrow band of patients in specific indications are able to benefit from CAR-Ts.
Overcoming the greatest obstacle to CAR-T adoption: neurotoxicity
At ImmixBio, we aim to change that paradigm by being the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity. By overcoming neurotoxicity, we aim to expand into indications that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies).
Our strategy is to:
Build on the proliferation of cell therapy expertise across the U.S. to deliver FDA approval submissions in AL amyloidosis and select immune-mediated diseases for NXC-201, our highly differentiated cell therapy candidate.
Demonstrate the power of overcoming neurotoxicity, divorcing the classical relationship between toxicity and efficacy.
Continue to expand into new indications and advance new cell therapies with similar transformative potential.
Our Story
ImmixBio was founded in 2012 by a driven physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent expert and an impact-driven founding family office.
Since then, we have demonstrated a consistent track record of execution yielding over 100 patients treated in clinical trials and are now advancing toward an FDA approval submission in relapsed/refractory AL Amyloidosis supported by the ongoing NEXICART-2 US (NCT06097832) and NEXICART-1 ex-US (NCT04720313) clinical trials for our next-generation CAR-T cell therapy NXC-201. Our clinical results have been presented at premier venues including: American Society of Hematology, American Society for Gene and Cell Therapy, and published in Clinical Cancer Research, Haematologica, and others.
We are fortunate to report that NXC-201 initial response rate of 92% and complete response rate of 69% in relapsed/refractory AL Amyloidosis has been observed from the Phase 1b/2a NEXICART-1 (NCT04720313) study (as of May 10, 2024). NXC-201 has has been awarded Orphan Drug Designation (ODD) by both the US FDA and EU European Commission in AL Amyloidosis.
Accelerated by our team’s unrelenting drive and expertise across cell therapy and other modalities as well as indications, paired with our execution track record, we believe we are uniquely positioned to effect a better future for patient communicates around the globe.
Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
LEAD U.S. SITE INITIATED
Memorial Sloan Kettering Cancer Center announced as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
MILESTONES
2ND HALF 2021
NASDAQ Initial Public Offering
1ST HALF 2022
IMMX Cell Therapy Research & Development Task Force Formed
2ND HALF 2022
R&D Group identified NXC-201, global commercialization rights secured
Early Phase 1 clinical data in Multiple Myeloma: zero neurotoxicity, single-day duration CRS (high-dose) uniquely suited to AL Amyloidosis and immune-mediated disease. No neurotoxicity across first 58 patients treated.
1ST HALF 2023
2023 ASGCT Late-Breaking Oral Presentation
2ND HALF 2023
2023 ASH Oral Presentation
FDA Orphan Drug Designation: AL Amyloidosis
FDA IND Clearance
U.S. Site Activation
2024
2024 ASGCT Late-Breaking Oral Presentation
NXC-201 U.S. Clinical Trial Doses First Patient (met mid-2024 guidance)
Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
FUTURE PLANS
Initial Clinical Data Release for NXC-201 in AL Amyloidosis (U.S. Patients)
We anticipate the first insights into our groundbreaking treatment, showcasing its potential and efficacy.
4Q 2024Interim Clinical Trial Data for NXC-201 in AL Amyloidosis
Stay tuned for progressive updates revealing ongoing results and impacts of our innovative therapy on U.S. patients.
2Q/3Q 2025Interim Clinical Trial Data for New Immune-Mediated Disease Indications
Witness the expansion into new ‘blue ocean’ immune-mediated disease indications, as we broaden our impact and explore additional therapeutic possibilities.
4Q 2025Final Clinical Trial Data for NXC-201 in AL Amyloidosis
Prepare for comprehensive outcomes, providing a full spectrum of data on our treatments.
2Q/3Q 2026WORLD CLASS TEAM
Our executive team hails from UCLA, Goldman Sachs, Roche, AstraZeneca and GSK, and has a proven track record working together.
Our board members are former senior members of Prometheus Biosciences (sold to Merck), as well as hedge fund and financial experts, and have been board members during many recent biopharmaceutical acquisitions valued at nearly $20 billion.
Harvard, Memorial Sloan Kettering, and Stanford members comprise our scientific advisory board.
LEADERSHIP TEAM
Ilya Rachman, MD PhD
Chief Executive Officer
Gabriel Morris, BA
Chief Financial Officer
Graham Ross, MBChB, FFPM
Chief Medical Officer
David Marks, MBBS, PhD
Chief Medical Officer, Cell Therapy
Gerhard Bauer
Head of Cell Therapy Manufacturing
SCIENTIFIC ADVISORY BOARD
Heather Landau, MD
Scientific Advisor
Michaela Liedtke, MD
Scientific Advisor
Suzanne Lentzsch, MD
Scientific Advisor
Marko Radic, PhD
Scientific Advisor
Vaishali Sanchorawala, MD
Scientific Advisor
Gary Schiller, MD
Scientific Advisor
Do you or a loved one suffer from AL Amyloidosis?
Discover if you qualify for our clinical trial and take a proactive step towards potential groundbreaking treatment. Join us in advancing care and contributing to medical research that could change lives.
HEAR FROM THE TEAM
Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and immune-mediated diseases. Hear their insights and learn about the passion that drives our mission forward.